News

The initial goal of this proof-of-concept phase Ib trial is to establish the maximum tolerated dose of PXD101 used in combination with carboplatin and/or paclitaxel, two drugs widely

Inovio is working closely on this project with Dr Connie Schmaljohn, chief of the department of molecular virology at the US Army Medical Research Institute of Infectious Diseases

The first indication that the company is seeking approval for is in the treatment of seizures associated with Lennox-Gastaut syndrome, a severe form of epilepsy that develops in

By the end of 2005, Nabi intends to announce preliminary safety and immunogenicity results from its European phase II study into NicVax, and be in a position to

Actiq is the first medication approved for the management of breakthrough cancer pain in patients with malignancies who are already receiving and who are tolerant to opioid therapy

News of Merck’s intended equity buy runs concurrent to Geron’s plans to offer six million shares of its common stock in an underwritten offering made from effective shelf

ImClone Systems intends to use the UltiMAb system to develop human antibody product candidates against its disease targets, which are primarily in the area of oncology. Under the

The agreement enables Ambion to adapt its microRNA platforms to detect, quantify, and functionally characterize microRNA sequences discovered by Rosetta. The resulting products will facilitate basic and applied

In the study of more than 5000 patients, the drug was shown to reduce the risk of heart attacks, strokes and death by 16% in high-risk patients with